

-20-

WE CLAIM:

1. Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a hydrate thereof, or mixtures thereof.
5
2. Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a hydrate thereof, or mixtures thereof, having an X-ray diffraction pattern which comprises the following peaks: 6.8 ± 0.1 , 10.9 ± 0.1 , 14.2 ± 0.1 and $16.6 \pm 0.1^\circ$ in 2θ ; when the pattern is obtained from a copper radiation source ($\text{CuK}\alpha$; $\lambda = 1.54056 \text{ \AA}$).
10
3. The crystalline mono-hydrochloride of claim 2 having an X-ray diffraction pattern which further comprises the following peaks: 6.3 ± 0.1 , 7.2 ± 0.1 , 12.5 ± 0.1 and $17.0 \pm 0.1^\circ$ in 2θ .
15
4. A pharmaceutical composition comprising a salt of any one of claims 1-3 and a pharmaceutical carrier.
20
5. A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3.
- 25 6. A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3.
- 30 7. A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3.

-21-

8. The compound of any one of claims 1-3 for use in a method of treating a human body by therapy.
9. The compound of claim 8 for use in treating non-Hodgkins lymphoma.
10. The compound of claim 8 for use in treating glioblastoma.
11. The compound of claim 8 for use in treating non-small cell lung cancer.
12. The use of a compound of any one of claims 1-3 for the manufacture of a medicament for the treatment of non-Hodgkins lymphoma.
13. The use of a compound of any one of claims 1-3 for the manufacture of a medicament for the treatment of glioblastoma.
14. The use of a compound of any one of claims 1-3 for the manufacture of a medicament for the treatment of non-small cell lung cancer.